Literature DB >> 20138827

Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes.

Junji Kozawa1, Kohei Okita, Akihisa Imagawa, Hiromi Iwahashi, Jens J Holst, Kazuya Yamagata, Iichiro Shimomura.   

Abstract

Incretin secretion and effect on insulin secretion are not fully understood in patients with type 2 diabetes. We investigated incretin and insulin secretion after meal intake in obese and non-obese Japanese patients with type 2 diabetes compared to non-diabetic subjects. Nine patients with type 2 diabetes and 5 non-diabetic subjects were recruited for this study. Five diabetic patients were obese (BMI > or = 25) and 4 patients were non-obese (BMI < 25). In response to a mixed meal test, the levels of immunoreactive insulin during 15-90 min and C-peptide during 0-180 min in non-obese patients were significantly lower than those in obese patients. Total GLP-1 and active GIP levels showed no significant difference between obese and non-obese patients throughout the meal tolerance test. In addition, there were no significant differences between diabetic patients and non-diabetic subjects. In conclusion, incretin secretion does not differ between Japanese obese and non-obese patients with type 2 diabetes and non-diabetic subjects. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20138827     DOI: 10.1016/j.bbrc.2010.01.134

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

Review 1.  Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies.

Authors:  S Calanna; M Christensen; J J Holst; B Laferrère; L L Gluud; T Vilsbøll; F K Knop
Journal:  Diabetologia       Date:  2013-02-03       Impact factor: 10.122

2.  Impact of incretin on early-phase insulin secretion and glucose excursion.

Authors:  Jie Shen; Zhi Chen; Chaofeng Chen; Xiao Zhu; Yajuan Han
Journal:  Endocrine       Date:  2013-01-03       Impact factor: 3.633

3.  Impaired secretion of total glucagon-like peptide-1 in people with impaired fasting glucose combined impaired glucose tolerance.

Authors:  Fang Zhang; Xialian Tang; Hongyi Cao; Qingguo Lü; Nali Li; Yupu Liu; Xiangxun Zhang; Yuwei Zhang; Mingming Cao; Jun Wan; Zhenmei An; Nanwei Tong
Journal:  Int J Med Sci       Date:  2012-09-07       Impact factor: 3.738

4.  Incretin responses to oral glucose load in Japanese non-obese healthy subjects.

Authors:  Etsuko Nagai; Tomoyuki Katsuno; Jun-Ichiro Miyagawa; Kosuke Konishi; Masayuki Miuchi; Fumihiro Ochi; Yoshiki Kusunoki; Masaru Tokuda; Kazuki Murai; Tomoya Hamaguchi; Mitsuyoshi Namba
Journal:  Diabetes Ther       Date:  2011-02-10       Impact factor: 2.945

5.  β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians.

Authors:  Daisuke Yabe; Yutaka Seino; Mitsuo Fukushima; Susumu Seino
Journal:  Curr Diab Rep       Date:  2015-06       Impact factor: 4.810

6.  Plasma gastric inhibitory polypeptide and glucagon-like peptide-1 levels after glucose loading are associated with different factors in Japanese subjects.

Authors:  Norio Harada; Akihiro Hamasaki; Shunsuke Yamane; Atsushi Muraoka; Erina Joo; Kazuyo Fujita; Nobuya Inagaki
Journal:  J Diabetes Investig       Date:  2011-06-05       Impact factor: 4.232

7.  Dipeptidyl peptidase-4 inhibitors are effective in Japanese type 2 diabetic patients with sustained endogenous insulin-secreting capacity, a higher body mass index and insulin resistance.

Authors:  Junji Kozawa; Tetsuhiro Kitamura; Hitoshi Nishizawa; Tetsuyuki Yasuda; Norikazu Maeda; Michio Otsuki; Kohei Okita; Hiromi Iwahashi; Hideaki Kaneto; Tohru Funahashi; Akihisa Imagawa; Iichiro Shimomura
Journal:  J Diabetes Investig       Date:  2012-11-23       Impact factor: 4.232

8.  Effects of glucose and meal ingestion on incretin secretion in Japanese subjects with normal glucose tolerance.

Authors:  Shunsuke Yamane; Norio Harada; Akihiro Hamasaki; Atsushi Muraoka; Erina Joo; Kazuyo Suzuki; Daniela Nasteska; Daisuke Tanaka; Masahito Ogura; Shin-Ichi Harashima; Nobuya Inagaki
Journal:  J Diabetes Investig       Date:  2012-02-20       Impact factor: 4.232

9.  Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes.

Authors:  Z F Kang; Y Deng; Y Zhou; R R Fan; J C N Chan; D R Laybutt; J Luzuriaga; G Xu
Journal:  Diabetologia       Date:  2012-11-28       Impact factor: 10.122

Review 10.  Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies.

Authors:  Salvatore Calanna; Mikkel Christensen; Jens J Holst; Blandine Laferrère; Lise L Gluud; Tina Vilsbøll; Filip K Knop
Journal:  Diabetes Care       Date:  2013-10       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.